Oral diabetes drug category shows large increase in professional health journal advertising through September 2013

Advertisers in professional health journals purchased about 70,063 total pages through September 2013, a 6% decrease year-over-year, according to  Kantar Media . Cancer Therapy Products continue to be the top drug class advertising by both pages and dollars. All five of the top product classes by pages show growth when compared to 2012; however, Diabetes Insulin, which is sixth on the list shows a 45% decrease.

Top 5 Print Ad Drug Classes (Pages): Jan. – September 2013

  1. Cancer Therapy Products – 7,065 pages (+12%)
  2. Anticoagulants Oral – 3,145 pages (+32%)
  3. Diabetes Oral – 1,751 pages (+253%)
  4. Immunologic Agents – 1,337 pages (+121%)
  5. Biological Response Modifiers – 1,244 pages (+15%)

The percentage changes compare January – September 2013 to that same time period in 2012. For more information on these ad insights or other data, let one of us know.

Kantar Media sets the standard for accurate, comprehensive competitive advertising intelligence in the professional healthcare arena. Check back next month for updated data on the top products, classes, companies and category movers year-to-date.

Search article